SOUTH SAN FRANCISCO - Cytokinetics , Incorporated (NASDAQ:CYTK), currently valued at approximately $5 billion in market capitalization, has announced the appointment of Robert E. Landry to its Board ...

Appointment Deepens Financial and Operational Expertise of Boardas Company Approaches Potential Commercialization SOUTH SAN ...

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is ...

Cytokinetics Inc is a biopharmaceutical company. It is engaged in the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of ...

Inspire Investing LLC boosted its position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 7.8% in the fourth quarter, according to the company in its most recent 13F filing ...

We recently published a list of 10 Stocks That Analysts Are Talking About. In this article, we are going to take a look at where Cytokinetics, Incorporated (NASDAQ:CYTK) stands against other stocks ...

Robert F. Smith (born 1962) grew up in a primarily Black, middle-class neighborhood in Denver, Colorado. His parents, who were both school principals with doctoral degrees, instilled in Smith deep ...

Shares of Cytokinetics CYTK gained 2.2% on Wednesday after the company began enrolling patients in its mid-stage study of CK-4021586 (CK-586), a cardiac myosin inhibitor, for treating heart ...

Cytokinetics' aficamten shows strong potential in the $3B U.S. oHCM market, despite competition from Bristol Myers’ Camzyos. Stifel sets a $80 price target, highlighting catalysts expected over ...